IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma

Conclusions: We discovered new druggable targets expressed by chemoresistant ES cells, xenografts, and relapsed human tumors. Joint suppression of these newfound targets, in concert with IGF-1R or mTOR blockade, should improve clinical outcomes.

Source: JNCI - August 29, 2016 Category: Cancer & Oncology Authors: Lamhamedi-Cherradi, S.-E., Menegaz, B. A., Ramamoorthy, V., Vishwamitra, D., Wang, Y., Maywald, R. L., Buford, A. S., Fokt, I., Skora, S., Wang, J., Naing, A., Lazar, A. J., Rohren, E. M., Daw, N. C., Subbiah, V., Benjamin, R. S., Ratan, R., Priebe, W., M Tags: Article Source Type: research